|Merrimack Pharmaceuticals Inc -- USA Stock|| |
USD 9.67 0.04 0.41%
Chief Scientific Officer and Sr. VP of Research
Dr. Ulrik B. Nielsen, Ph.D., is Director of Company. He has served as a member of our board of directors since January 2015 and is one of our cofounders. Dr. Nielsen led our research and drug discovery from when he joined us in 2002 to January 2015, including as our Senior Vice President and Chief Scientific Officer from March 2009 until January 2015. Dr. Nielsen has served as President and Chief Executive Officer of Torque Inc., a biotechnology company, since January 2015. Dr. Nielsen also served as Chief Executive Officer of Silver Creek Pharmaceuticals, Inc., a majority owned subsidiary of ours, from July 2010 to March 2014
Age: 43 SVP Since 2015
Nielsen holds a Ph.D. in molecular biology and an M.S. in biochemistry from the University of Copenhagen.
The company has return on total asset (ROA)
of (60.21) %
which means that it has lost $60.21 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (19.0) %
meaning that it created substantial loss on money invested by shareholders.
|Found 1 records|
|Reed Clark||Dimension Therapeutics Inc|
Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Merrimack Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 72 people.Merrimack Pharmaceuticals Inc (MACK) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 72 people. Merrimack Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.